Drugs /

tac regimen

Back to Drugs List

Overview

NCI Definition [1]:
A chemotherapy regimen consisting of docetaxel, doxorubicin and cyclophosphamide, used as a neoadjuvant or adjuvant treatment for breast cancer.

Clinical Trials

View Clinical Trials for tac regimen

Tac regimen has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating tac regimen, 1 is phase 3 (1 open).

ATM Loss, ATM Mutation, and ATR Loss are the most frequent biomarker inclusion criteria for tac regimen clinical trials.

Breast carcinoma is the most common disease being investigated in tac regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tac Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tac regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

NCIT ID [1]:
C63435

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.